Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018 07; 24(7):968-977.
View in:
PubMed
subject areas
Animals
Cell Line, Tumor
Disease Models, Animal
Esophageal Neoplasms
Gene Amplification
Humans
Mice
Mitogen-Activated Protein Kinase Kinases
Piperidines
Protein Kinase Inhibitors
Protein Tyrosine Phosphatase, Non-Receptor Type 11
Proto-Oncogene Proteins p21(ras)
Pyridones
Pyrimidines
Pyrimidinones
Stomach Neoplasms